By: Jennifer Brown
New research from the University of Iowa answers a question that has vexed cystic fibrosis (CF) researchers for almost 25 years: Why don’t mice with CF gene mutations develop the life-threatening lung disease that affects most people with CF?
The research team, led by Michael Welsh, discovered an answer to this long-standing scientific puzzle, and in doing so, identified a proton pump that could be a target for new CF therapies. They published their results Jan. 29 in the journal Science.
“Since the first CF mouse was reported in 1992, I have been asked hundreds of times, ‘Why don’t CF mice have respiratory host-defense defects and develop lung infections?’” says Welsh, who is a professor of internal medicine, molecular physiology, and biophysics; a Howard Hughes Medical Institute Investigator; and director of the Pappajohn Biomedical Institute at the UI.
In answering this question, Viral Shah, first author on the study and a student in the Medical Scientist Training Program at the UI Carver College of Medicine, homed in on the thin layer of liquid that covers the mice’s airways, i.e., the tracheal and bronchial passages. Shah and his colleagues studied the liquid’s acidity, the importance of which was revealed in earlier UI studies using pigs with CF. That work showed that the CF pigs had an abnormally acidic airway liquid, and that increased acidity impaired the ability of their airways to fight off infection.
Shah explains that, normally, two opposing processes control airway acidity. The cystic fibrosis transmembrane conductance regulator (CFTR) channel secretes bicarbonate, a base. That process is countered by the secretion of protons—an acid. The balance tightly controls the acidity of liquid in the airways.
In people, pigs, and mice with CF, the CFTR channel is lost, stopping the flow of bicarbonate into the airways. When that happens in people and pigs, their airway liquid becomes more acidic, reducing their ability to fight infection. But in mice, the airway liquid does not become more acidic, and they are not prone to infection. That fact led the scientists to ask what secretes acid into the airways of people and pigs that is missing in the mice. They discovered that a proton pump called ATP12A is responsible.
Shah and his colleagues made the discovery by comparing airway tissue from humans, pigs, and mice. The scientists showed that blocking ATP12A in airway tissue from pigs and humans with CF reduces the acidity of their airway liquid and restores their airways’ defenses against infection. Conversely, putting the ATP12A proton pump into the airways of CF mice increases the acidity of the liquid and predisposes the CF mice to bacterial infections.
“This discovery helps us understand the cause of lung disease in people with CF. It may also identify ATP12A as a new therapeutic target,” Shah says. “We wonder if blocking ATP12A in people with CF could halt the progression of lung disease.”
Shah adds that targeting ATP12A could potentially be helpful for all forms of CF, regardless of a patient’s CFTR mutation, because ATP12A is independent of CFTR.
The CF pig model was developed in 2008 by Welsh and his research team at the UI, with colleagues from the University of Missouri. The CF pig closely mimics human CF disease, including the lung problems absent from CF mice, and has proven very useful in advancing our understanding of CF lung problems.
In addition to Shah and Welsh, the research team on the Science study included David Meyerholz, Xiao-Xiao Tang, Leah Reznikov, Mahmoud Abou Alaiwa, Sarah Ernst, Philip Karp, Christine Wohlford-Lenane, Kristopher Heilmann, Mariah Leidinger, Patrick Allen, Joseph Zabner, Paul McCray, Lynda Ostedgaard, David Stoltz, and Christoph Randak.
The research was funded in part by grants from the National Institutes of Health, the Cystic Fibrosis Foundation, and the Roy J. Carver Charitable Trust.